Jazz Pharmaceuticals PLC
(NAS:JAZZ)
$
121.59
-1.05 (-0.86%)
Market Cap: 7.35 Bil
Enterprise Value: 10.93 Bil
PE Ratio: 17.13
PB Ratio: 1.76
GF Score: 85/100 Jazz Pharmaceuticals PLC at Bank of America Healthcare Conference Transcript
May 10, 2022 / 07:40PM GMT
Release Date Price:
$144.03
(+1.52%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
All right, everybody. Thanks for joining us for today's afternoon session of the Bank of America Annual Healthcare Conference. My name is Jason Gerberry, I cover biotech and spec pharma. Pleased to be introducing our next company presenter, Jazz Pharmaceuticals. We've got CEO, Bruce Cozadd; Dan Swisher, President; and Philip Jochelson who is the Therapeutic Head of CNS. So Bruce has like a couple of minutes of prepared remarks, and then we'll jump into Q&A.
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
So how long is our session, if I talk for the whole session, then no Q&A, right?
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
My clock is running at 27.
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
So Jason, it's great to be here. It's great to see people in person, it's just been
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot